Industry

− New Data Follow Recent U.S. FDA Approval of AMVUTTRA® (vutrisiran) as First RNAi Therapeutic to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Patients with ATTR-CM – − Vutrisiran Favorably Impacted Echocardiographic Systolic and Diastolic Function – − Vutrisiran Treatment Led to Maintenance or Improvement in Functional Capacity, Health Status, and … [Read more…]

CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus … [Read more…]

Cloud-based, innovative, AI-powered technologies enable the streamlined delivery of leading clinical services and scaled operations in advanced Imaging CAMBRIDGE, Mass. & LOUISVILLE, Ky.–(BUSINESS WIRE)–ConcertAI’s TeraRecon, a leader in integrating advanced imaging workflows with clinical AI, has announced an expanded partnership with 3DR® Labs, a leading provider of 3D medical image post-processing and clinically integrated AI … [Read more…]

MIDDLETOWN, Pa.–(BUSINESS WIRE)–Diopsys, Inc. has settled all claims with the Department of Justice related to its Nova ERG device marketing activities from the period of 2015-2021. The settlement provides for a series of guaranteed payments totaling $1,225,000 and contingent payments up to a maximum of $13,025,000 to be made over a period of 6 years. … [Read more…]

LITTLE ELM, Texas–(BUSINESS WIRE)–Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2024. Further details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 28, 2025 with the U.S. Securities and Exchange Commission. The Company’s revenues for … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “HIV Drugs – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for HIV Drugs was valued at US$32.8 Billion in 2024 and is projected to reach US$44.5 Billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Anesthesia Devices – A Global Market Overview” report has been added to ResearchAndMarkets.com’s offering. The global anesthesia devices market is estimated to be valued at US$17.1 billion in 2024, and is projected to reach US$27.3 billion by 2030, registering a CAGR of 8.1% from 2024 to 2030. The global anesthesia devices market is … [Read more…]

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company“), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under … [Read more…]

Manufacturers of food equipment materials, nonfood compounds and chemicals can now certify their products to NSF’s PFAS-Free guideline, demonstrating a commitment to human and planet health. AUCKLAND, New Zealand–(BUSINESS WIRE)–NSF, a leading global public health and safety organization, today announced the launch of NSF Certification Guideline 537: PFAS-Free Products for Nonfood Compounds and Food Equipment … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 (Mesutoclax) in combination with BTK inhibitor orelabrutinib as a first-line therapy for patients with … [Read more…]